Pricing transparency: Continuing the conversation - Webcast replay


Webcast details

Drug cost scrutiny and a call for greater drug price transparency are a consistent topic in the news. This pressure is coupled with a commitment from our new executive branch of government to decrease drug pricing. In response, pharmaceutical manufacturers need to ensure they have insight and a defendable narrative to describe their pricing practices which includes, how they set launch prices, their price increase patterns and how they facilitate financial access to their drugs. 

In this recorded webcast, our team of subject matter specialists discuss the following:

  • What is Pricing Transparency?
  • Our point of view on why transparency is an important topic of discussion
  • Key considerations and success factors for becoming a more transparent organization
    • Do you know the cumulative effect of your pricing strategy over the past 5 years across your product portfolio?
    • Do you understand the impact of your pricing strategy on various patient populations?
    • Do you have the ability to analyze and understand the data used to support launch price decisions and price increase decisions?
    • Is your pricing committee agile enough to adjust to evolving risks that a new political environment might bring?

Webcast contact

Please contact Melissa Cornett with any questions regarding this event. 

CPE credits

This webcast does not offer CPE credits.

If you have any questions concerning continuing professional education (CPE), you can find answers here to frequently asked questions concerning CPE webcast participation.

Contact us

Beth Paul
US Strategic Thought Leader, National Professional Services Group

Pat Durbin
US Standard Setting Leader, National Professional Services Group

David Schmid
International Accounting Leader, National Professional Services Group

Follow us